Targeted treatment of pruritus: a look into the future
- 11 January 2011
- journal article
- review article
- Published by Wiley in British Journal of Dermatology
- Vol. 165 (1), 5-17
- https://doi.org/10.1111/j.1365-2133.2011.10217.x
Abstract
Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease‐activated receptor 2, serine proteases, cathepsin S, peripheral mu‐ and kappa‐opioid receptors, interleukin‐31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas‐related G protein‐coupled receptors. In the spinal cord, gastrin‐related peptide and its receptor, as well as substance P and its receptor neurokinin receptor‐1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito‐affective aspects of the disease.Keywords
This publication has 163 references indexed in Scilit:
- Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itchPain, 2010
- Toll-like receptor 7 mediates pruritusNature Neuroscience, 2010
- Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanismNature Neuroscience, 2010
- Cathepsin S Elicits Itch and Signals via Protease-Activated ReceptorsJournal of Investigative Dermatology, 2010
- Sensory Neuron-Specific GPCR Mrgprs Are Itch Receptors Mediating Chloroquine-Induced PruritusCell, 2009
- Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosisEuropean Journal of Human Genetics, 2009
- TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanismsProceedings of the National Academy of Sciences of the United States of America, 2009
- Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndromeThe Journal of Experimental Medicine, 2009
- Structures and biological functions of IL-31 and IL-31 receptorsCytokine & Growth Factor Reviews, 2008
- Adjuvant treatment of atopic eczema: assessment of an emollient containing N‐palmitoylethanolamine (ATOPA study)Journal of the European Academy of Dermatology and Venereology, 2007